This article discusses the potential of using high-productivity membrane chromatography to achieve intensified and flexible virus manufacturing.
Most vaccines available today are still manufactured using antiquated, low-yield, and labor-intensive process technologies in capital-intensive facilities. This lack of manufacturing flexibility drives high cost of goods, diminishes affordability for developing countries, and reduces the market incentive to address smaller patient populations. Improved manufacturing technologies can enable more efficient and cost-effective processes. This article discusses the potential of using high-productivity membrane chromatography to achieve intensified and flexible virus manufacturing.
Download the
Vaccine Development and Manufacturing 2017 ebook.
Pharmaceutical Technology and BioPharm International
eBook: Vaccine Development and Manufacturing 2017
November 2017
Pages: 39-44
When referring to this article, please cite it as R. Jacquemart et al., “Achieving Intensification and Flexibility in Virus Purification with Next-Generation Chromatography Tools,” Pharmaceutical Technology and BioPharm International Vaccine Development and Manufacturing 2017 eBook (November 2017).
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.